TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12843690

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: C‐reactive protein and von Willebrand factor levels
Number of subjects: 300
Study: 10885587

Group type: EXPERIMENTAL
Intervention: Ibuprofen 7 mg/kg in suspension
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 or 400mg as effervescent granules
Number of subjects: 103
Study: 9058443

Group type: EXPERIMENTAL
Intervention: Inulin (30-35 g/d) for 1 week
Number of subjects: 0
Study: 8125424

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg/day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 3586003

Group type: EXPERIMENTAL
Intervention: Short form of the Jenkins Activity Survey (21 scored items)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Long form of the Jenkins Activity Survey (44 items)
Number of subjects: 1248
Study: 29536216

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28288613

Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill (alter G®) treatment, 20 min sessions, 2-3 times per week for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 120
Study: 25402332

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23530100

Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) assessment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 12-gene recurrence score (RS) in T3 MMR-intact (MMR-I) patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Mismatch repair (MMR) gene deficiency
Number of subjects: 162
Study: 21953799

Group type: EXPERIMENTAL
Intervention: Telecare program
Number of subjects: 291

Group type: COMPARATOR
Intervention: Self-monitoring blood glucose
Number of subjects: 291
Study: 18555997

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV 6/11/16/18 vaccine
Number of subjects: 814
Study: 16869257

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study: 12556649

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily
Number of subjects: 440

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine (after dosage adjustment)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Losartan/HCTZ (after dosage adjustment)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 440

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine (in African Americans)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Losartan (in African Americans)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine (in mostly Hispanic patients)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Losartan (in mostly Hispanic patients)
Number of subjects: 440
Study: 10865310

Group type: EXPERIMENTAL
Intervention: Optisol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Organ culture
Number of subjects: 24
Study: 9305484

Group type: COMPARATOR
Intervention: Standard oral rehydration solution (20 g/L glucose, 94 mmol/L sodium, 292 mOsm/kg osmolality)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Polymeric glucose isotonic solution enriched with glutamine (18 g/L Glucidex 12, 14.6 g/L glutamine, 94 mmol/L sodium, 282 mOsm/kg osmolality)
Number of subjects: 6
Study: 8409300

Group type: EXPERIMENTAL
Intervention: cisapride 20 mg b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cisapride 20 mg b.i.d. + ranitidine 150 mg b.i.d.
Number of subjects: 60
Study: 3891488

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril long-term treatment (75 or 150 mg daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Captopril (after 6.5 months)
Number of subjects: 8
Study: 30019604

Group type: EXPERIMENTAL
Intervention: Wives' reports of IPV victimization
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Husbands' reports of IPV perpetration
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Factors associated with discordant reporting
Number of subjects: 717
Study: 31069579

Group type: EXPERIMENTAL
Intervention: HIPEC treatment
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Preoperative systemic chemotherapy
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (no HIPEC)
Number of subjects: 282
Study: 30172703

Group type: EXPERIMENTAL
Intervention: Purified CD34+ cells (PCCs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMNCs)
Number of subjects: 50
Study: 26947102

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Collaborative educational program
Number of subjects: 199
Study: 25182247

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1504
Study: 22939198

Group type: EXPERIMENTAL
Intervention: Wake-up strokes (WUS)
Number of subjects: 17398

Group type: COMPARATOR
Intervention: Stroke while awake (SWA)
Number of subjects: 17398
Study: 20368065

Group type: EXPERIMENTAL
Intervention: AcrySof IQ ReSTOR SN6AD3 IOL (Group test)
Number of subjects: 70

Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN60D3 IOL (Group control)
Number of subjects: 70
Study: 18950009

Group type: EXPERIMENTAL
Intervention: Ultracision-harmonic scalpel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Routine operation
Number of subjects: 31
Study: 16215542

Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Frequency doubled Nd : YAG laser trabeculoplasty (YLT)
Number of subjects: 35
Study: 12668512

Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 323

Group type: COMPARATOR
Intervention: CRT off
Number of subjects: 323
Study: 10647267

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8706533

Group type: EXPERIMENTAL
Intervention: Complete object event (removal of the screen revealing a single, connected rectangle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broken object event (removal of the screen revealing an interrupted rectangle with a gap)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectangle event (removal of the screen revealing a rectangle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-shape event (removal of the screen revealing a cross-shaped object)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline control conditions
Number of subjects: 0
Study: 1659437

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily) plus sumatriptan (300 mg orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus sumatriptan (300 mg orally)
Number of subjects: 10
Study: 6108728

Group type: EXPERIMENTAL
Intervention: Alfentanyl 6.4 micrograms/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alfentanyl 1.6 and 3.2 micrograms/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alfentanyl
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 5
Study: 31593582

Group type: EXPERIMENTAL
Intervention: Ovarian biopsying followed by autotransplantation of fragmented cortical tissue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control ovary (non-biopsied)
Number of subjects: 20
Study: 29326577

Group type: EXPERIMENTAL
Intervention: Active tDCS + Active PES
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active tDCS + Sham PES
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham tDCS + Active PES
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham tDCS + Sham PES
Number of subjects: 128
Study: 25793773

Group type: EXPERIMENTAL
Intervention: 3 day regimen (2 injections of 7 mg/kg in 3 days)
Number of subjects: 163

Group type: COMPARATOR
Intervention: 7 day regimen (3 injections of 4 mg/kg per injection in 7 days)
Number of subjects: 163
Study: 24011061

Group type: EXPERIMENTAL
Intervention: Group Family Nurse Partnership (gFNP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 21140160

Group type: EXPERIMENTAL
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH)
Number of subjects: 90
Study: 20003311

Group type: EXPERIMENTAL
Intervention: Seven-day leadership course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-source feedback alone (control)
Number of subjects: 0
Study: 16455831

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-dose budesonide
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 49
Study: 14671247

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide for eligible participants)
Number of subjects: 6105
Study: 11414008

Group type: EXPERIMENTAL
Intervention: Attention focused on subjective contours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention focused on overlapping figures
Number of subjects: 0
Study: 9226286

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both Atenolol and Metoprolol
Number of subjects: 28
Study: 7679610

Group type: EXPERIMENTAL
Intervention: Bleomycin administered intravenously on a weekly basis
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Oral etoposide therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Radiation treatment regimens (8 Gy in a single fraction and 20 Gy in ten fractions)
Number of subjects: 1
Study: 3689634

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg day‐1) for 9 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28940192

Group type: EXPERIMENTAL
Intervention: Oral language programme (N = 103)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Active control programme targeting motor skills (N = 105)
Number of subjects: 208
Study: 26829343

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Physical Therapy (PFPT) - 4 sessions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no PFPT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (PFPT and Control)
Number of subjects: 54
Study: 25060372

Group type: EXPERIMENTAL
Intervention: Prophylaxis with second-generation cephalosporins
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Post-operative antibiotic duration >48 h
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Intubation time of 24 to 48 h
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Ventilation >48 h
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Major infections
Number of subjects: 5158

Group type: EXPERIMENTAL
Intervention: Transfusion by surgery type (excluding left ventricular assist device procedures/transplant)
Number of subjects: 5158
Study: 23079491

Group type: COMPARATOR
Intervention: Working Memory Training (WMT)
Number of subjects: 0
Study: 19757213

Group type: EXPERIMENTAL
Intervention: Berberine (300 mg orally three times daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no berberine)
Number of subjects: 78
Study: 18228568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858
Study: 16162694

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg bid (CIC 640)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ciclesonide 1280 microg bid (CIC 1280)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg bid (FP 880)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 880 microg bid (FP 1760)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 60
Study: 12867607

Group type: EXPERIMENTAL
Intervention: Impermeable bedding covers
Number of subjects: 279

Group type: COMPARATOR
Intervention: Non-impermeable bedding covers (control)
Number of subjects: 279
Study: 10381042

Group type: EXPERIMENTAL
Intervention: MTX 15-20 mg/week
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8689188

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 59
Study: 1568727

Group type: EXPERIMENTAL
Intervention: Hyperlipidemia associated with primary biliary cirrhosis
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Detailed serum lipid profiles in 50 consecutive PBC patients
Number of subjects: 312
Study: 6131683

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 5 min after recovery (group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 15 min after recovery (group II)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 40 micrograms kg‐1 30 min after recovery (group III)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Org NC 45 40 micrograms kg‐1 (group IV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Org NC 45 80 micrograms kg‐1 (group V)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by Org NC 45 (groups I, II, III)
Number of subjects: 25
Study: 31719135

Group type: EXPERIMENTAL
Intervention: Women with ischemic stroke
Number of subjects: 19652
Study: 28700844

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 731
Study: 25594377

Group type: EXPERIMENTAL
Intervention: On-line (OL) condition with visual feedback during movement production
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-planned (PP) condition without visual feedback during movement production
Number of subjects: 0
Study: 23332657

Group type: EXPERIMENTAL
Intervention: 1‐to‐1 pelvic floor muscle training (PFMT) and a self‐instruction manual (SIM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Self‐instruction manual (SIM) alone
Number of subjects: 140
Study: 21428467

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and IL-2 as maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and IL-2 therapy
Number of subjects: 0
Study: 19207300

Group type: COMPARATOR
Intervention: Passive forearm motion sensitivity in children
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive forearm motion sensitivity in adults
Number of subjects: 30
Study: 16884465

Group type: EXPERIMENTAL
Intervention: Caudal group (1 ml.kg(‐1) 0.25% bupivacaine)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no caudal)
Number of subjects: 47
Study: 12527981

Group type: EXPERIMENTAL
Intervention: Cycling at 70% FCC cadence
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cycling at 85%, 100%, 115%, and 130% FCC cadences
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cycling at 60%, 80%, and 100% maximal aerobic power
Number of subjects: 10
Study: 10615738

Group type: EXPERIMENTAL
Intervention: Naltrexone only (50 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naltrexone with nicotine patches (50 mg once daily + 21 mg/24-hour for first 8 weeks, 14 mg/24-hour for last 4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo with nicotine patches
Number of subjects: 100
Study: 9008982

Group type: EXPERIMENTAL
Intervention: Brand's Essence of Chicken (BEC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1523998

Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Adriamycin (ADM) instillation at a dose of 500 micrograms/ml, 3 times per week for 3 weeks
Number of subjects: 63
Study: 6497936

Group type: EXPERIMENTAL
Intervention: 40 mg tamoxifen daily for 2 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (matched healthy females)
Number of subjects: 23
Study: 30963353

Group type: EXPERIMENTAL
Intervention: Insulin-loaded liposomal chitosan gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29735461

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 0
Study: 27036515

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (traditional therapy)
Number of subjects: 76
Study: 24732026

Group type: EXPERIMENTAL
Intervention: PPI + LLP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AA + LLP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LLP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PPI
Number of subjects: 51

Group type: COMPARATOR
Intervention: HE
Number of subjects: 51

Group type: COMPARATOR
Intervention: AA + HE
Number of subjects: 51
Study: 22115712

Group type: EXPERIMENTAL
Intervention: EGP‐437 (dexamethasone phosphate) via iontophoresis at 1.6 mA‐min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EGP‐437 (dexamethasone phosphate) via iontophoresis
Number of subjects: 40
Study: 20530395

Group type: EXPERIMENTAL
Intervention: Facilitated intervention group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Self-directed intervention group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (self-directed)
Number of subjects: 36
Study: 18083469

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg IV for 10 minutes followed by 0.3 mcg/kg IV for 50 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propacetamol (2 g IV for 10 minutes)
Number of subjects: 30
Study: 16026220

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with adjunctive parent component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) without parent component
Number of subjects: 0
Study: 11925385

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment in patients with elevated progesterone levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH administration during suppression of endogenous gonadotrophin secretion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethinyl estradiol intake
Number of subjects: 0
Study: 10215217

Group type: EXPERIMENTAL
Intervention: Long-term implantation of left ventricular assist devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study: 8691565

Group type: EXPERIMENTAL
Intervention: G-CSF (200 micrograms/m2 iv) administration starting 24 hrs after chemotherapy (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: G-CSF (200 micrograms/m2 iv) administration after a febrile episode of 38 degrees C with neutropenia (Group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: G-CSF (Group A)
Number of subjects: 57
Study: 2178487

Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam
Number of subjects: 65

Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 65
Study: 420326

Group type: EXPERIMENTAL
Intervention: True acupuncture treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pseudo-acupuncture (random needling)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment control periods
Number of subjects: 3
Study: 30458636

Group type: EXPERIMENTAL
Intervention: Conventional phototherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensive phototherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blue light‐emitting diodes (LED) phototherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 26063788

Group type: EXPERIMENTAL
Intervention: Your Moment of Truth (YMOT) intervention, 6 sessions of 2 hours each
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Your Moment of Truth (YMOT) intervention
Number of subjects: 1543
Study: 25795947

Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Soy protein (SP)
Number of subjects: 68
Study: 24138994

Group type: EXPERIMENTAL
Intervention: Yoga (20‐min group session, physical poses, once per week for 12 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Social support (leaderless discussion group, same schedule as yoga)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Yoga and Social Support (both groups)
Number of subjects: 92
Study: 20690869

Group type: EXPERIMENTAL
Intervention: Hamstring stretching in sitting (SI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hamstring stretching in standing (ST)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No stretching (control)
Number of subjects: 36
Study: 18976268

Group type: EXPERIMENTAL
Intervention: hard occlusal splint (HS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: soft occlusal splint (SS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: non-occluding occlusal splint (NS)
Number of subjects: 42
Study: 16397167

Group type: EXPERIMENTAL
Intervention: Vitamins (folic acid, vitamin B12, and B6)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 12375220

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (No Atropine)
Number of subjects: 55
Study: 9951672

Group type: EXPERIMENTAL
Intervention: ECCE with intraocular lens implantation
Number of subjects: 110